IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $54.00 at Guggenheim

IDEAYA Biosciences (NASDAQ:IDYA) had its price target hoisted by Guggenheim from $50.00 to $54.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

IDYA has been the topic of a number of other reports. Wedbush reiterated an “outperform” rating and set a $52.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, March 31st. Wall Street Zen lowered shares of IDEAYA Biosciences from a “buy” rating to a “sell” rating in a report on Saturday, February 21st. UBS Group initiated coverage on shares of IDEAYA Biosciences in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, January 22nd. Finally, Truist Financial set a $65.00 target price on shares of IDEAYA Biosciences in a report on Monday. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.44.

IDEAYA Biosciences Stock Down 1.4%

IDEAYA Biosciences stock opened at $32.35 on Tuesday. The firm has a market cap of $2.84 billion, a PE ratio of -24.69 and a beta of 0.02. IDEAYA Biosciences has a 52-week low of $15.84 and a 52-week high of $39.28. The company’s 50 day moving average is $32.38 and its two-hundred day moving average is $32.62.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The business had revenue of $10.88 million for the quarter, compared to analyst estimates of $5.95 million. IDEAYA Biosciences’s quarterly revenue was up 55.7% compared to the same quarter last year. During the same quarter last year, the company earned ($1.49) earnings per share. On average, equities research analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEAYA Biosciences

In other news, Director Jeffrey Stein acquired 50,000 shares of IDEAYA Biosciences stock in a transaction dated Monday, March 2nd. The shares were acquired at an average cost of $32.96 per share, for a total transaction of $1,648,000.00. Following the acquisition, the director owned 54,281 shares of the company’s stock, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of IDYA. GSK plc acquired a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $46,093,000. Baker BROS. Advisors LP raised its holdings in shares of IDEAYA Biosciences by 54.6% in the 3rd quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock valued at $89,125,000 after purchasing an additional 1,156,716 shares in the last quarter. State Street Corp raised its holdings in shares of IDEAYA Biosciences by 27.6% in the 4th quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after purchasing an additional 893,707 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of IDEAYA Biosciences by 11.8% in the 4th quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock valued at $248,344,000 after purchasing an additional 758,117 shares in the last quarter. Finally, First Turn Management LLC acquired a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $25,017,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences News Summary

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: Positive topline registrational data from the OptimUM-02 Phase 2/3 trial: darovasertib + crizotinib improved median PFS to 6.9 months vs. 3.1 months for control (HR 0.42; 95% CI: 0.30–0.59), meeting the primary endpoint — a result that supports regulatory and commercial upside in metastatic uveal melanoma. PR Newswire
• Positive Sentiment: Market reaction/press coverage pushed the stock sharply higher overnight and in early trading as outlets reported the trial success, creating momentum and heightened investor attention. Investing.com article
• Positive Sentiment: Several firms raised price targets and issued bullish ratings after the data — notable raises include Wedbush to $58 (Outperform), Wells Fargo to $48 (Overweight) and Guggenheim to $54 (Buy) — signaling significant analyst upside expectations. Benzinga The Fly
• Neutral Sentiment: Goldman Sachs raised its price target to $35 but kept a “Neutral” rating — a reminder that not all sell-side desks expect an immediate re-rating into the highest target bands. Benzinga
• Negative Sentiment: Analyst/media caveats and regulatory risk remain — some commentary notes that approval and commercialization are not automatic despite strong PFS, so development and labeling/regulatory paths still carry execution risk. Seeking Alpha
• Negative Sentiment: Profit‑taking and volatility after the sizable overnight rally are likely driving the intraday pullback despite the positive fundamentals — volume is elevated and short-term traders may be locking gains.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.